



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	85.78
Trade Time:	4:15 PM ET Jul 18, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	74.13 - 147.17
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 10, 2018
[Anti-PD-L1 Immunotherapy Plus ABRAXANE[®] Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study](#)

Jul 9, 2018
[Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia](#)

Jul 2, 2018
[Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018](#)

Jun 28, 2018
[Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes](#)

Jun 19, 2018
[Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi](#)

Upcoming Events [\[View all \]](#)

Jul 26, 2018 9:00 AM ET
[Celgene Corporation Q2 2018 Earnings Conference Call](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 7, 2018
[Annual Report \(10-K\)](#)

Apr 30, 2018
[Proxy Statement \(DEF 14A\)](#)

May 4, 2018
[Quarterly Report \(10-Q\)](#)

Oct 26, 2017
[Quarterly Report \(10-Q\)](#)

Jul 27, 2017
[Quarterly Report \(10-Q\)](#)

